Company: SWKH
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001628280-25-040420
Chunk: 19

Company: SWK Holdings Corp
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 19
---
 STATEMENTS OF INCOME

(in thousands, except per share data)

 Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024Revenues:Finance receivable interest income, including fees$8,543 $9,986 $19,255 $21,021 Pharmaceutical development 1,190 804 2,153 1,083 Other 319 57 476 103 Total revenues10,052 10,847 21,884 22,207 Costs and expenses:Provision (benefit) for credit losses761 4,095 (704)9,392 Loss on impairment of intangibles assets— 5,771 — 5,771 Interest expense1,155 1,119 2,285 2,375 Pharmaceutical manufacturing, research and development expense645 520 1,403 1,050 Change in fair value of acquisition-related contingent consideration— (4,900)— (4,900)Depreciation and amortization expense19 421 38 935 General and administrative expense2,843 2,920 6,120 5,604 Income from operations4,629 901 12,742 1,980 Other income (expense), netUnrealized net gain (loss) on warrants347 226 (77)131 Net gain on exercise and cancellation of warrants— 675 — 444 Loss on sale of assets— — (82)— Net gain (loss) on marketable investments37 (19)(68)(162)Realized gain on early payment of finance receivable— — 1,729 — Gain (loss) on revaluation of finance receivables— 2,495 (3,727)2,495 Realized and unrealized foreign currency transaction gains (losses)(451)437 (138)524 Income before income tax expense4,562 4,715 10,379 5,412 Income tax expense1,026 1,035 2,304 1,264 Net income$3,536 $3,680 $8,075 $4,148 Net income per shareBasic$0.29 $0.30 $0.66 $0.33 Diluted$0.29 $0.